These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24492369)

  • 1. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.
    Wooley M; Miller B; Krishna G; Hershberger E; Chandorkar G
    Antimicrob Agents Chemother; 2014; 58(4):2249-55. PubMed ID: 24492369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects.
    Aiudi A; Miller B; Krishna G; Adedoyin A; Xiao A
    Fundam Clin Pharmacol; 2016 Dec; 30(6):625-633. PubMed ID: 27473285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.
    Chandorkar G; Xiao A; Mouksassi MS; Hershberger E; Krishna G
    J Clin Pharmacol; 2015 Feb; 55(2):230-9. PubMed ID: 25196976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.
    Monogue ML; Stainton SM; Baummer-Carr A; Shepard AK; Nugent JF; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.
    Miller B; Hershberger E; Benziger D; Trinh M; Friedland I
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3086-91. PubMed ID: 22450972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
    Kakara M; Larson K; Feng HP; Shiomi M; Yoshitsugu H; Rizk ML
    J Infect Chemother; 2019 Mar; 25(3):182-191. PubMed ID: 30528208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
    Melchers MJ; Mavridou E; Seyedmousavi S; van Mil AC; Lagarde C; Mouton JW
    Antimicrob Agents Chemother; 2015; 59(6):3373-6. PubMed ID: 25824214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
    Nicolau DP; De Waele J; Kuti JL; Caro L; Larson KB; Yu B; Gadzicki E; Zeng Z; Rhee EG; Rizk ML
    Int J Antimicrob Agents; 2021 Apr; 57(4):106299. PubMed ID: 33567333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
    Monogue ML; Pettit RS; Muhlebach M; Cies JJ; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6578-6584. PubMed ID: 27550351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
    Sucher AJ; Chahine EB; Cogan P; Fete M
    Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
    Chandorkar G; Huntington JA; Gotfried MH; Rodvold KA; Umeh O
    J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
    Arrieta AC; Ang JY; Zhang Z; Larson KB; Yu B; Johnson MG; Rhee EG; Feng EH; Rizk ML
    Pediatr Pulmonol; 2020 Aug; 55(8):2025-2032. PubMed ID: 32421928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
    Xiao AJ; Miller BW; Huntington JA; Nicolau DP
    J Clin Pharmacol; 2016 Jan; 56(1):56-66. PubMed ID: 26096377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S; Pai MP; Lodise TP
    J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
    Larson KB; Patel YT; Willavize S; Bradley JS; Rhee EG; Caro L; Rizk ML
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
    Kullar R; Wagenlehner FM; Popejoy MW; Long J; Yu B; Goldstein EJ
    J Antimicrob Chemother; 2017 Mar; 72(3):900-905. PubMed ID: 27999024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
    VanScoy B; Mendes RE; Nicasio AM; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2809-14. PubMed ID: 23629705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.